As part of its advocacy program in the United States, ACRO submits regulatory comments to U.S. regulators. This RFI response, submitted by ACRO to the FDA in August 2026, on the Expedited Investigational New Drug (IND) pilot program to shorten the time it takes from drug identification to first-in-human (FIH) study, can be found below.